A Double-blind, Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of TAK-475 50 mg, 100 mg, or Placebo When Co-administered With Atorvastatin (10 mg to 40 mg) in Subjects With Primary Hypercholesterolemia

NCT00143676 Phase 3 COMPLETED

The purpose of this study is to determine the efficacy of lapaquistat acetate, once daily (QD), on lowering cholesterol in subjects already taking atorvastatin.

Details

Lead sponsor	Takeda
Phase	Phase 3
Status	COMPLETED
Enrolment	448
Start date	2005-08
Completion	2006-08

Conditions

• Hypercholesterolemia

Interventions

• Lapaquistat acetate and atorvastatin
• Lapaquistat acetate and atorvastatin
• Atorvastatin

Primary outcomes

• Change from Baseline in Low Density Lipoprotein cholesterol — Week 24 or Final Visit

Countries

United States